Nuclear Medicine/Radiopharmaceuticals Market Worth 5.26 Billion - KAIT Jonesboro, AR - Region 8 News, weather, sports

Nuclear Medicine/Radiopharmaceuticals Market Worth 5.26 Billion USD by 2023

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

SOURCE MarketsandMarkets

PUNE, India, June 14, 2018 /PRNewswire/ --

According to a new market research report "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023", published by MarketsandMarkets™, the global market is expected to grow at a CAGR of 5.9% during the forecast period, to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 250 market data Tables and 34 Figures spread through 213 Pages and in-depth TOC on "Nuclear Medicine/Radiopharmaceuticals Market"

https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

Early buyers will receive 10% customization on this report 

Growth in this market can primarily be attributed to factors such as the increasing incidence and prevalence of target conditions such as cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.

TC-99m dominated the SPECT Nuclear Medicine Market in 2017 

Based on type, the Nuclear Medicine Market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. Diagnostic radiopharmaceuticals have been further segmented into SPECT and PET radiopharmaceuticals. SPECT radiopharmaceuticals include Tc-99m, Tl-201, Ga-67, I-123, and other SPECT isotopes. In 2017, the Tc-99m segment accounted for the largest share of the nuclear medicine SPECT Radiopharmaceuticals Market. Tc-99m is used in a majority of diagnostic nuclear medicine procedures such as MPI, cardiac ventriculography, functional brain imaging, sentinel-node identification, immunoscintigraphy, blood pool labeling, sulfur colloid for spleen scan, and diagnosing various bone ailments.

The oncology application segment is expected to dominate the PET Nuclear Medicine Market during the forecast period 

The major application areas of PET nuclear medicine include oncology, cardiology, neurology, and others. The oncology segment is projected to account for the largest share of the PET Nuclear Medicine Market during the forecast period. The large share of this segment can be attributed to the use of F-18 which is a key isotope used in oncology applications. It is used to analyze glucose metabolism in the heart, lungs, and brain, which aids in cancer diagnosis. It also helps in monitoring cancer treatment and stages, particularly colorectal cancer, Hodgkin's disease, NHL, melanoma, breast cancer, and lung cancer.

Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=417

North America dominated the market in 2018 

North America is expected to account for the largest share of the Nuclear Medicine Market in 2018, followed by Europe. The large share of this region can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the region.

Cardinal Health (US), GE Healthcare (US), and Curium (France) are the key players in the Nuclear Medicine Market. Other players involved in this market are Bayer (Germany), Lantheus Medical Imaging (US), Advanced Accelerator Applications (France), and Jubilant Life Sciences (India).

Know more about the Nuclear Medicine/Radiopharmaceuticals Market: 

https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Visit Our Blog: http://www.marketsandmarketsblog.com/market-reports/healthcare

Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets


©2017 PR Newswire. All Rights Reserved.

Powered by Frankly